The Latest Research on CRPC with Bone Metastases : Abstracts + "Beyond the Abstracts"

Recent Abstracts

CRPC w/ bone metastases

July 23, 2019

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.
CRPC w/ bone metastases

May 9, 2019

Prognostic Value of 18F-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated with Docetaxel.
CRPC w/ bone metastases

May 1, 2019

Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States.
CRPC w/ bone metastases

January 11, 2019

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
CRPC w/ bone metastases

January 4, 2019

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives.
CRPC w/ bone metastases

January 3, 2019

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223.
CRPC w/ bone metastases

December 20, 2018

Reversibility of castration resistance status after Radium-223 dichloride treatment: Clinical evidence and Review of the literature.
CRPC w/ bone metastases

December 3, 2018

Evaluating radium-223 response in metastatic castration-resistant prostate cancer with imaging.
CRPC w/ bone metastases

November 23, 2018

The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer
CRPC w/ bone metastases

October 15, 2018

Efficacy of Radium-223 in Bone-metastatic Castration-resistant Prostate Cancer with and Without Homologous Repair Gene Defects

View All (10 Pages)

Beyond the Abstracts

CRPC w/ bone metastases

April 7, 2017

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer-Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT: Beyond the Abstract
CRPC w/ bone metastases

January 5, 2017

Prostate Cancer Cure is Possible: Beyond the Abstract
CRPC w/ bone metastases

February 11, 2015

The use of radium 223 dichloride in a multidisciplinary approach for treating metastatic castration-resistant prostate cancer, "Beyond the Abstract," by Elisa Borsò

View All (1 Page)

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.